Synergo® RITE for Bladder Cancer

In spite of the variety of treatments available, the rate of tumor recurrence and disease progression have been high among Intermediate to High-risk patients. The major goals in treating patients with non muscle invasive bladder cancer are to prevent the high number of recurrences and to prevent muscle invasive progression. 

In spite of the variety of treatments available, the rate of tumor recurrence and disease progression have been high among Intermediate to High-risk patients. The major goals in treating patients with non muscle invasive bladder cancer are to prevent the high number of recurrences and to prevent muscle invasive progression. 

 

The Synergo® device combines local radiofrequency (microwave), tissue thermal elevation (heating) of the bladder wall, with simultaneous flushing of the urinary bladder with a cooled chemotherapeutic agent (ThermoChemotherapy).

 

The RF and chemotherapy are administered locally through a special unique transurethral RF ablation applicator equipped with a miniaturised antenna and five thermometers, all mounted inside a silicone foley catheter. The applicator is inserted into the urinary bladder through the urethra. All treatment data is processed and monitored by the Synergo® computer, so bladder tissue temperatures remain constant and stable throughout the treatment (in the region of 42°C) 

 

The Synergo transurethral RF applicator performs three main functions: 

  • Radiofrequency radiation (local, non-ionising) of the bladder walls, also uniformly heating (hyperthermia) them by means of a small RF-emitting antenna. 

  • Temperature monitoring by sensitive thermocouples in several locations on the bladder wall and urethra. 

  • Circulation of the cooled chemotherapeutic drug into and out of the bladder (RF ChemoHyperthermia).

 

Synergo® is the effective, safe and simple tri-modal combination of non-ionising RF radiation, cooled chemotherapy and tissue thermotherapy, to treat intermediate and high risk NMIBC patients, who in many cases failed previous treatments or have no alternatives. Synergo® is the only proven technology for NMIBC according to EAU and already obtained NICE's IPG and MIB. Being the only treatment in almost five decades to be found superior to BCG in first line, Synergo® is also an attractive option in times of BCG shortage, or for BCG-

intolerant and contraindicated patients. By reducing recurrences and therefore surgeries, offering this ambulatory treatment also frees up valuable operating theatre time. Synergo® yielded 92% Complete Response Rate in CIS patients and 80% bladder preservation rate in cystectomy candidates in 10-year-follow-ups. Based in the Netherlands, Medical Enterprises Group, manufacturer of the Synergo technology is focused on developing minimally invasive therapeutic technologies which provide benefits for both patient and healthcare system.

© 2020 Pinpoint Scotland Ltd (Registered in Scotland No. SC068684)

Urology News is published by Pinpoint Scotland Ltd, 9 Gayfield Square, Edinburgh, EH1 3NT. Tel: 0131 557 4184 -  www.urologynews.uk.com

  • Facebook
  • Twitter
  • YouTube